中文 EN
首页 / / Our history
2023
Reading frequency:335  Updated on:2023-07-24
★ Chiheal Biomed completed its Series A financing, further strengthening its investment in R&D. The CRO, CMO, and CDMO models became increasingly mature. The first fast-follow innovative drug completed a transfer transaction.
PREV: 2022
NEXT: Taiji Group
Copyright 2024 Nanjing Chiheal Bio Medicine Technology Co..Ltd All rights reserved.